Glucagon-stimulated copeptin response In Children: A Proof-Of-Concept Study
-
By
-
Indirli, Rita
-
Giacchetti, Federico
-
Profka, Eriselda
-
Rodari, Giulia
-
Petria, Iulia
-
Arosio, Maura
-
Giavoli, Claudia
-
Mantovani, Giovanna
-
Ferrante, Emanuele
-
May 27, 2026
-
Clinical Scorecard: Copeptin Response to Glucagon Stimulation in Pediatric Patients: A Preliminary Investigation
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | Children tested for suspected growth hormone deficiency without PPS |
| Care Setting | |
Key Highlights
- Study involved 20 children (9 females, mean age 10.3 years)
- GST induced a copeptin response as observed in the study
- Median copeptin concentration increased from 4.1 pmol/L to 10.6 pmol/L
- Peak copeptin concentration observed at 150 minutes post-injection
- No adverse events recorded during the study
Guideline-Based Recommendations
Diagnosis
- Further studies are warranted to assess GST accuracy in diagnosing PPS
Management
- GST is safe and effective for enhancing copeptin secretion as per study findings
Monitoring & Follow-up
- Measure plasma copeptin levels before and after GST as indicated in the study
Risks
- No adverse events reported in the study
Patient & Prescribing Data
GST can be utilized to evaluate copeptin response in children with suspected growth hormone deficiency
Clinical Best Practices
- Conduct GST to assess copeptin response in pediatric patients as per study findings
- Monitor copeptin levels at multiple time points post-glucagon injection as indicated in the study
Related Resources & Content
